Blue Fin Capital Inc. Sells 544 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Blue Fin Capital Inc. trimmed its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 4.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,743 shares of the financial services provider’s stock after selling 544 shares during the quarter. Blue Fin Capital Inc.’s holdings in iShares Biotechnology ETF were worth $1,459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Column Capital Advisors LLC bought a new stake in iShares Biotechnology ETF during the 3rd quarter valued at approximately $49,000. Premier Path Wealth Partners LLC purchased a new position in iShares Biotechnology ETF during the fourth quarter valued at $207,000. StrategIQ Financial Group LLC boosted its holdings in shares of iShares Biotechnology ETF by 9.2% during the 4th quarter. StrategIQ Financial Group LLC now owns 5,013 shares of the financial services provider’s stock valued at $681,000 after buying an additional 422 shares in the last quarter. Brookstone Capital Management grew its position in shares of iShares Biotechnology ETF by 4.1% in the 4th quarter. Brookstone Capital Management now owns 6,753 shares of the financial services provider’s stock worth $917,000 after buying an additional 269 shares during the period. Finally, Congress Wealth Management LLC DE purchased a new stake in shares of iShares Biotechnology ETF in the 3rd quarter worth about $265,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

NASDAQ IBB traded up $2.31 during trading hours on Friday, reaching $132.96. 1,804,184 shares of the company’s stock traded hands, compared to its average volume of 1,700,513. iShares Biotechnology ETF has a 52-week low of $111.83 and a 52-week high of $141.16. The firm has a 50-day simple moving average of $133.61 and a 200 day simple moving average of $130.05. The firm has a market cap of $7.27 billion, a PE ratio of 17.35 and a beta of 0.86.

iShares Biotechnology ETF Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 27th. Shareholders of record on Friday, March 22nd were paid a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.38%. The ex-dividend date was Thursday, March 21st.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.